VIRTUUS Children's Study: Validating Injury to the Renal Transplant Using Urinary Signatures in Children

VIRTUUS 儿童研究：利用儿童尿液特征验证肾移植损伤

• 批准号: 10178059
• 负责人: Sandra Amaral
• 金额: $ 61.31万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-10 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10178059
• 关键词: Acute; Adolescent; Adult; Allografting; Area Analyses; Area Under Curve; BK Virus; Biological Markers; Biopsy; CXCL10 gene; Canada; Caring; Cells; Child; Childhood; Childhood Injury; Clinical; Clinical Trials; Cohort Studies; Core Biopsy; Creatinine; Development; Diagnosis; Diagnostic; End stage renal failure; Enrollment; Failure; Future; Gene Expression; Genes; Gold; Half-Life; Health; Hemorrhage; Hospitalization; Immune response; Immunity; Immunologic Surveillance; Immunologics; Incidence; Individual; Injury; Kidney Diseases; Kidney Transplantation; Life Expectancy; Measures; Medicine; Messenger RNA; Operative Surgical Procedures; Organ Transplantation; Outcome; Plasminogen Activator Inhibitor 1; Prognostic Marker; Prospective Studies; Public Health; Quality of life; RNA; ROC Curve; Receiver Operating Characteristics; Regimen; Research; Research Design; Ribosomal RNA; Risk; Sampling; Sampling Errors; Sedation procedure; Sensitivity and Specificity; Serum; Specificity; Time; Transplant Recipients; Transplantation; Tubular formation; United States; United States National Institutes of Health; Urine; Virus; Virus Diseases; antibody-mediated rejection; base; clinical decision-making; clinical efficacy; clinical practice; diagnosis standard; diagnostic biomarker; genetic signature; graft failure; improved; individualized medicine; kidney allograft; member; metabolomics; minimally invasive; noninvasive diagnosis; post-transplant; predictive modeling; prognostic; prognostic model; programs; urinary; xanthosine

PROJECT SUMMARY The overarching objectives of this proposal are to investigate whether existing urinary mRNA and metabolite profiles, which are diagnostic and prognostic for early renal allograft injury in adults, can be validated in pediatric kidney transplant recipients. Children with end-stage renal disease (ESRD) have a life expectancy at least 20 years shorter than children without renal disease. During their lifetime, most children with ESRD will require several kidney transplants to prolong duration and quality of life. Each transplant incurs new surgical and immunological risk. Despite substantial gains in improving short-term allograft outcomes through improved immunosuppressive regimens, the half-life of a kidney transplant is still only 10-12 years. Thus, there is a critical need to prolong allograft survival. A major hindrance to advancing long-term outcomes is the inability to reliably detect early allograft injury before clinical manifestations arise. Early allograft injury results from acute cellular or antibody- mediated rejection or early emergence of viruses, primarily BK virus which leads to BK virus nephropathy. This project’s specific aims are: 1) to validate highly sensitive and specific adult urinary cell mRNA signatures to diagnose and predict acute cellular rejection (ACR) in pediatric recipients, 2) to evaluate the clinical efficacy of urine metabolite profiling to diagnose and prognosticate ACR in pediatric recipients and to validate the sensitivity and specificity of a combined adult kidney allograft urinary mRNA and metabolite signature for ACR in pediatric recipients and 3) to investigate if BKV-VP-1 mRNA levels in urinary cells are diagnostic of BK virus associated nephropathy, and if urinary cell levels of Plasminogen Activator Inhibitor-1 mRNA and serum creatinine, predict future graft failure. These aims will be achieved through the collaborative effort of key pediatric kidney transplant programs across the United States and Canada, supported by two outstanding labs at Weill Cornell Medicine and Stanford. This study’s results will advance the ability to identify and characterize early allograft injury in pediatric kidney allograft recipients through non-invasive immune surveillance. By doing so, we will create opportunities to better inform clinical decision-making, improving practice paradigms to promote positive long-term graft outcomes.

项目概要 该提案的首要目标是调查现有的尿液 mRNA 和 代谢物谱可用于成人早期同种异体移植肾损伤的诊断和预后 在儿科肾移植受者中得到验证。 患有终末期肾病 (ESRD) 的儿童的预期寿命比正常儿童至少短 20 年 没有肾脏疾病的儿童，大多数患有 ESRD 的儿童一生中都需要多个肾脏。 移植以延长生命周期和提高生活质量。每次移植都会带来新的手术和免疫风险。 尽管通过改善免疫抑制在改善短期同种异体移植结果方面取得了实质性进展 肾移植的半衰期仍然只有10-12年，因此迫切需要延长。 同种异体移植物存活的一个主要障碍是无法可靠地早期检测。 临床表现出现之前的同种异体移植物损伤是由急性细胞或抗体引起的。 介导的排斥反应或病毒早期出现，主要是 BK 病毒，导致 BK 病毒肾病。 该项目的具体目标是：1）验证高度敏感和特异性的成人泌尿细胞 mRNA 用于诊断和预测儿科受者急性细胞排斥 (ACR) 的特征，2) 评估 尿液代谢物分析对儿科接受者 ACR 诊断和预测的临床疗效 验证成人肾同种异体移植尿 mRNA 和代谢物的综合敏感性和特异性 儿科接受者中 ACR 的签名，以及 3) 研究泌尿细胞中的 BKV-VP-1 mRNA 水平是否 BK 病毒相关性肾病的诊断，以及尿细胞纤溶酶原激活物抑制剂-1 水平的情况 mRNA 和血清肌酐可预测未来的移植失败。这些目标将通过协作来实现。 美国和加拿大的主要儿科肾移植项目的努力，得到了两个机构的支持 威尔康奈尔医学院和斯坦福大学的杰出实验室这项研究的结果将提高识别能力。 并通过非侵入性免疫来表征儿科同种异体肾移植受者的早期同种异体移植损伤 通过这样做，我们将创造机会更好地为临床决策提供信息，从而改善。 实践范例以促进积极的长期反腐败结果。

项目成果

Sex-based differences in screening and recognition of pre-diabetes and type 2 diabetes in pediatric primary care.

• DOI: 10.1111/ijpo.12699
• 发表时间: 2021-03
• 期刊: Pediatric obesity
• 影响因子: 3.8
• 作者: Vajravelu ME;Lee JM;Amaral S;Kelly A
• 通讯作者: Kelly A

Secular Trends in Survival Outcomes of Kidney Transplantation for Children: Is the Future Bright Enough?

儿童肾移植生存结果的长期趋势：未来足够光明吗？

• DOI: 10.2215/cjn.00370120
• 发表时间: 2020
• 期刊: Clinical journal of the American Society of Nephrology : CJASN
• 作者: Amaral,Sandra

Caregiver perspectives of pre-transplant evaluation in children.

• DOI: 10.1007/s00467-021-05354-8
• 发表时间: 2022-08
• 期刊: Pediatric nephrology (Berlin, Germany)
• 作者: Salmon EC;Barr LG;Hill DL;Shea JA;Amaral S
• 通讯作者: Amaral S

Early detection of SARS-CoV-2 and other infections in solid organ transplant recipients and household members using wearable devices.

• DOI: 10.1111/tri.13860
• 发表时间: 2021-06
• 期刊: Transplant international : official journal of the European Society for Organ Transplantation
• 作者: Keating BJ;Mukhtar EH;Elftmann ED;Eweje FR;Gao H;Ibrahim LI;Kathawate RG;Lee AC;Li EH;Moore KA;Nair N;Chaluvadi V;Reason J;Zanoni F;Honkala AT;Al-Ali AK;Abdullah Alrubaish F;Ahmad Al-Mozaini M;Al-Muhanna FA;Al-Romaih K;Goldfarb SB;Kellogg R;Kiryluk K;Kizilbash SJ;Kohut TJ;Kumar J;O'Connor MJ;Rand EB;Redfield RR;Rolnik B;Rossano J;Sanchez PG;Alavi A;Bahmani A;Bogu GK;Brooks AW;Metwally AA;Mishra T;Marks SD;Montgomery RA;Fishman JA;Amaral S;Jacobson PA;Wang M;Snyder MP
• 通讯作者: Snyder MP

Vitamin D and cardiovascular disease in chronic kidney disease.

• DOI: 10.1007/s00467-018-4088-y
• 发表时间: 2019-12
• 期刊: Pediatric nephrology (Berlin, Germany)
• 作者: Kaur G;Singh J;Kumar J
• 通讯作者: Kumar J